Updates
** Shares of drugmaker Corcept Therapeutics CORT.O soars as much as 91.7% to record high of $104.73
** Stock last up 83.6% at $100.29
** CORT says its experimental drug for ovarian cancer in combination with chemotherapy met the main goal of a late-stage trial
** Co says the drug, relacorilant, when combined with chemotherapy agent nab-paclitaxel, showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared with those treated with chemotherapy alone
** Canaccord Genuity analyst Edward Nash estimates peak sales of $1.3 billion for relacorilant by 2036
** Platinum-resistant ovarian cancer is a type of ovarian cancer that doesn't respond to platinum-based chemotherapy treatments, which are typically used as a first-line therapy
** Including session's moves, CORT shares more than double YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。